Researchers Find Immunity Protein That Ramps Up Inflammation, and Agents That Can Blo
http://www.sciencedaily.com/releases...0331165601.htm "The research team, led by Bill B. Chen, Ph.D., associate professor, Division of Pulmonary, Allergy and Critical Care Medicine, conducted experiments in which mice that lacked the ability to make Fbxo3 were infected with a strain of Pseudomonas bacteria, and found that they had better lung mechanics and longer survival than mice that still made the protein." Read more at link above.
Conclusions. The applied diagnostic criteria had no significant effect on the reported rate of ABPA prevalence. PMID: 31702121 [PubMed - as supplied by publisher]
The major cause of lung damage in cystic fibrosis (CF) is infection with bacterial pathogens, the most prevalent of which is Pseudomonas aeruginosa, chronically infecting ~60% patients by adolescence/adulthood (www.cysticfibrosis.org.uk/news/registry-report-2017). P. aeruginosa may be successfully eradicated, but frequently recurs and establishes biofilms resistant to antibiotics/host defences . Chronic P. aeruginosa is closely linked with pulmonary exacerbation frequency, faster lung function decline and earlier mortality . The huge antibiotic burden imposed upon patients and the resulting bacterial resist...
Inhaled and oral glutathione may benefit lung function in patients with cystic fibrosis (CF), although vitamin and mineral antioxidant supplementation does not appear to have a positive treatment effect, an updated Cochrane Review reveals.Reuters Health Information
We present a 23-year-old male with a history of cystic fibrosis (CF) with associated renal disease, bronchiectasis, pneumothorax, and distal intestinal obstruction syndrome admitted for CF exacerbation. Sputum culture was positive for methicillin resistant Staphylococcus aureus (MRSA). Chest imaging revealed extensive opacities in the left lung. His FEV1 during admission was 52% (baseline 70%). Allergy was consulted as inhaled vancomycin therapy was preferred, but the patient had previous vancomycin-induced reactions.
High antibiotic utilization is an essential element of life-saving care for cystic fibrosis (CF) patients. However, adverse drug reactions (ADRs) to antibiotics occur more commonly and discrete types of ADRs may differ in CF patients compared to the general population. Characterization of documented ADRs among CF patients is needed in order understand how antibiotic utilization can be improved for CF patients.
Allergic bronchopulmonary aspergillosis (ABPA) affects up to 15% of patients with cystic fibrosis (CF), representing a significant clinical challenge. It is especially a concern in the pediatric population given adverse effects of steroids in this population. Here we report on the use of omalizumab in the treatment of steroid-resistant ABPA in a pediatric patient with CF.
Reactions were much more common in patients with cystic fibrosis and those with previously identified environmental or drug allergies.Medscape Medical News
BackgroundChronic rhinosinusitis (CRS) is associated with bronchiectasis; however, this relationship has not been well studied in the United States (US) population. In this work we aimed to determine the prevalence of CRS among patients with bronchiectasis affiliated with a US tertiary medical center and identify which comorbid diseases are associated with the presence of CRS in patients with bronchiectasis.MethodsThis was a retrospective cohort study in which data were obtained from a large database warehouse at a tertiary care center. Patients with bronchiectasis were identified from 2007 to 2017 using diagnosis codes fr...
This study assessed omalizumab outcomes in real-world patients with allergic asthma stratified by pretreatment biomarker levels. METHODS: Patients with allergic asthma aged ≥12 years initiated on omalizumab with ≥12 months of data after index were identified in the Allergy Partners electronic medical records (2007-2018). Patients with ≥1 diagnosis of chronic obstructive pulmonary disease in combination with ≥10 pack-years of smoking, cystic fibrosis, Alpha-1 antitrypsin deficiency, bronchiectasis, interstitial lung disease, and sarcoidosis in the 12 months before or after index were excluded. Patients were...
PMID: 31550169 [PubMed - as supplied by publisher]